Pharvaris' Deucrictibant XR Shows 83% Attack Rate Reduction in HAE…

Event summary

Pharvaris' CHAPTER-3 study met primary endpoint with 83% attack rate reduction in HAE patients using deucrictibant XR vs. placebo (p<0.0001).
87% attack rate reduction observed in HAE Type 1 or Type 2 patients specifically.
All secondary efficacy endpoints met with statistical significance; well-tolerated safety profile demonstrated.
Company plans to submit NDA for deucrictibant XR prophylaxis in first half of 2027.
CHAPTER-4 long-term extension study and CREAATE study for AAE-C1INH ongoing.

The big picture

Pharvaris' positive CHAPTER-3 results position deucrictibant XR as a potential first-line oral prophylaxis option for HAE, addressing unmet needs in a market currently dominated by injectable therapies. The study's success across all HAE types strengthens Pharvaris' position in the bradykinin-mediated angioedema space, setting the stage for potential dual approvals (prophylaxis and on-demand treatment) that could redefine HAE management. The company's focus on oral administration with injectable-like efficacy aligns with broader industry trends toward patient-friendly drug formulations.

What we're watching

Regulatory Pathway: Whether the positive CHAPTER-3 results will translate into smooth NDA approval process for deucrictibant XR prophylaxis.
Commercial Strategy: How Pharvaris positions deucrictibant XR against existing HAE prophylaxis treatments in the market.
Pipeline Expansion: The pace at which Pharvaris advances deucrictibant for other bradykinin-mediated conditions beyond HAE.